Abstract
The notable clinical success of cancer immunotherapy using checkpoint blockade suggests that it is likely to form the foundation of curative therapy for many malignancies. However, checkpoint blockades do not achieve sustained clinical response in most patients and thus amounts of problems needed to be figured out. Regarding these challenges, the 2017 Chinese Lung Cancer Summit expert panel organized a forum on the 14th Chinese Lung Cancer Summit to formally discuss these controversies. Five consensuses finally were reached to guide the application of checkpoint blockades.
Original language | English (US) |
---|---|
Pages (from-to) | 428-436 |
Number of pages | 9 |
Journal | Translational Lung Cancer Research |
Volume | 7 |
Issue number | 3 |
DOIs | |
State | Published - Jun 1 2018 |
Bibliographical note
Publisher Copyright:© Translational lung cancer research.
Keywords
- Consensus
- Immunotherapy
- Lung cancer